Role of complement factor H and immunity in AMD: a novel transgenic model

补体因子 H 和免疫在 AMD 中的作用:一种新型转基因模型

基本信息

  • 批准号:
    8708875
  • 负责人:
  • 金额:
    $ 38.96万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-09-30 至 2017-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Age-related macular degeneration (AMD) is the leading cause of irreversible legal blindness in people over 60 years of age in the US, with over 1.8 million Americans affected by advanced disease. There is no proven effective therapy for the advanced atrophic form of the disease. Also, despite the recent advent of anti- vascular endothelial growth factor agents, the clinical outcomes for "wet" AMD remain suboptimal. The impact on quality of life is severe, often leading to drastic changes in life-style and significant anxiety and depression. Recent evidence suggests that chronic inflammation, likely directed towards subretinal debris generated from oxidative damage, may be important in the disease process. Genetic studies have consistently shown that a variant in complement factor H (Cfh), an important regulator of complement activation, is a strong risk factor for AMD. However, the mechanism by which Cfh is associated to the disease process is not well understood. We have recently generated chimeric Cfh transgenic mouse lines that model the Cfh variants associated to AMD. These mice develop findings consistent with early AMD. They also have a propensity to accumulate subretinal macrophages in the posterior pole. This last finding is intriguing, since some studies suggest that macrophages may be protective against AMD, while others imply that they promote disease progression. In this proposal we plan to use the Cfh transgenic mice to address three issues: 1. the role of the Cfh variants in regulating inflammation after different acute vs. chronic inflammatory stimuli, 2. determine which molecular interactions are affected by the Cfh variant (interactions of Cfh with c-reactive protein, or with glycosaminoglycans, or with other Cfh molecules), and how this effect may be relevant to AMD, and 3. determine the role of macrophages in the pathogenesis of AMD, and how that is affected by the Cfh variants. At the end of the study we hope to have a better understanding of the early pathogenesis of AMD, to have identified potential new therapeutic targets for early intervention, and to have generated a more robust animal model for the disease.
描述(由申请人提供):在美国,年龄相关性黄斑变性(AMD)是导致60岁以上人群不可逆转的法定失明的主要原因,超过180万美国人患有晚期疾病。对于这种疾病的晚期萎缩性形式,目前还没有被证明有效的治疗方法。此外,尽管最近出现了抗血管内皮生长因子药物,但“湿性”AMD的临床结果仍然不理想。对生活质量的影响是严重的,往往导致生活方式的剧烈变化和重大变化

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Rafael Ufret-Vincenty其他文献

Rafael Ufret-Vincenty的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Rafael Ufret-Vincenty', 18)}}的其他基金

Exploring Mechanisms in Retinal Development/Homeostasis, Retinal Immune Surveillance and Diabetic Retinopathy Using Forward Genetics
利用正向遗传学探索视网膜发育/稳态、视网膜免疫监视和糖尿病视网膜病变的机制
  • 批准号:
    10316653
  • 财政年份:
    2021
  • 资助金额:
    $ 38.96万
  • 项目类别:
Exploring Mechanisms in Retinal Development/Homeostasis - Admin. Supplement
探索视网膜发育/稳态的机制 - 管理。
  • 批准号:
    10636145
  • 财政年份:
    2021
  • 资助金额:
    $ 38.96万
  • 项目类别:
Exploring Mechanisms in Retinal Development/Homeostasis, Retinal Immune Surveillance and Diabetic Retinopathy Using Forward Genetics
利用正向遗传学探索视网膜发育/稳态、视网膜免疫监视和糖尿病视网膜病变的机制
  • 批准号:
    10672979
  • 财政年份:
    2021
  • 资助金额:
    $ 38.96万
  • 项目类别:
Role of complement factor H and immunity in AMD: a novel transgenic model
补体因子 H 和免疫在 AMD 中的作用:一种新型转基因模型
  • 批准号:
    8345535
  • 财政年份:
    2012
  • 资助金额:
    $ 38.96万
  • 项目类别:
Role of complement factor H and immunity in AMD: a novel transgenic model
补体因子 H 和免疫在 AMD 中的作用:一种新型转基因模型
  • 批准号:
    8546385
  • 财政年份:
    2012
  • 资助金额:
    $ 38.96万
  • 项目类别:

相似海外基金

Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.96万
  • 项目类别:
    Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.96万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 38.96万
  • 项目类别:
    Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.96万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 38.96万
  • 项目类别:
    Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.96万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.96万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.96万
  • 项目类别:
    Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 38.96万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
  • 批准号:
    2244994
  • 财政年份:
    2023
  • 资助金额:
    $ 38.96万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了